FinTechFunding

Zelira Therapeutics: Launches Zenivol in Australia

  • Zelira Therapeutics (ZLD) has launched its proprietary cannabinoid medicine, Zenivol, in Australia
  • The company has received approval from the Therapeutic Goods Administration’s (TGA) Special Access Scheme to launch the treatment
  • Zenivol is for patients with chronic insomnia and will be available through Zelira’s distribution partner, Health House
  • This announcement follows a successful clinical trial conducted by the University of Western Australia
  • Zelira is on track to launch five new products across global markets in 2020
  • Company shares are up 10 per cent on the market this morning, trading for 6.6 cents per share
Previous article
Saunders International: Awarded $26M defence contract
Next article
Elevations Credit Union: Selects Temenos Infinity
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Visa and TikTok Launch Creator Card, Enhancing Monetization for Influencers

New financial tool aims to streamline earnings for content creators.Highlights: Visa and TikTok have launched the new Creator...
FinTech

Nium and Coinbase Strengthen Global Stablecoin Settlement Partnership

The collaboration aims to enhance cross-border payments using stablecoins.Highlights: Nium partners with Coinbase to optimize stablecoin settlements.The collaboration...
FinTech

FCA Announces Second Cohort for AI Live Testing Initiative

New phase aims to improve integration of AI in financial services.Highlights: FCA launches second cohort for AI live...
FinTech

Cab Payments Strengthens Case Against Helios Blocking Takeover Bid

Cab Payments contests Helios Investment's actions regarding merger talks.Highlights: Cab Payments accuses Helios of blocking a crucial takeover...